RAPT Therapeutics, Inc. (RAPT) Financial Statements

RAPT Therapeutics, Inc. (RAPT) files with the U.S. Securities and Exchange Commission under CIK 0001673772. 10KGenie shows its annual and quarterly statements from SEC filings.

Key Figures, Fiscal Year 2024

Net Income
-$129.87 million
Total Assets
$240.32 million
Net Cash from Operations
-$83.30 million

Fiscal year ended Dec 31, 2024. Latest periodic SEC filing: Nov 6, 2025. Source: SEC filings (EDGAR XBRL).

Open the full financial statements for RAPT in 10KGenie

Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History